Atlas Trials

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

Clinical trial NCT03225924 · TERMINATED

Trial details

NCT number
NCT03225924
Sponsor
The Lymphoma Academic Research Organisation
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
DLBCL
Start date
2017-07-26
Primary completion
2019-10-18
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.